A + T ± status across MCI and dementia due to AD: a clinic-based, retrospective study

[1]  K. Blennow,et al.  Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid , 2021, Clinical chemistry and laboratory medicine.

[2]  W. Jagust,et al.  Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer’s Disease Pathophysiology , 2020, Biological Psychiatry.

[3]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[4]  Nick C. Fox,et al.  Consensus classification of posterior cortical atrophy , 2017, Alzheimer's & Dementia.

[5]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[6]  K. Blennow,et al.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.

[7]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[8]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[9]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[10]  K. Blennow,et al.  Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies , 2006, Clinical chemistry and laboratory medicine.